Tern Therapeutics develops transformative, one-time genetic treatments for rare diseases.
Tern Therapeutics has raised $3.7M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in September 2026.
Tern Therapeutics's investors include ATW Partners, Steve Oliveira.
Tern Therapeutics is headquartered in Washington, United States.
Tern Therapeutics develops transformative, one-time genetic treatments for rare diseases.
Tern Therapeutics is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Tern Therapeutics — Funding & Investors." VCBacked, September 25, 2026, https://www.vcbacked.co/company/tern-therapeutics. Accessed October 31, 2026.
VCBacked. (2026). Tern Therapeutics — Funding & Investors. Retrieved October 31, 2026, from https://www.vcbacked.co/company/tern-therapeutics
{{cite web |title=Tern Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/tern-therapeutics |website=VCBacked |access-date=October 31, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated